{
  "folder": "IC-027",
  "content": "{{knowledge objective\n|Identifiant=OIC-027-32-B\n|Item_parent=Prevention of foetal risks: infection, drugs, toxic substances, irradiation\n|Item_parent_short=Prevention of foetal risks: infection, drugs, toxic substances, irradiation\n|Rank=B\n|Intitul\u00e9=M\u00e9dicaments et grossesse : conna\u00eetre les cons\u00e9quences des principaux m\u00e9dicaments \u00e0 risque\n|Description=None\n|Rubric=Positive diagnosis\n|Contributors=Alexandre Vivanti, Philippe Deruelle\n|Order=32}}\n\n{| class=\"wikitable\"\n|'''Family'''\n|'''INN (trade name)'''\n|'''Type of malformation(s)'''\n|'''Procedure'''\n|-\n|Vitamin A derivatives\n|Isotretinoin\n\n(Roaccutane<sup>\u00ae</sup>, Acnetrait<sup>\u00ae</sup>, Curacne<sup>\u00ae</sup>, Procuta<sup>\u00ae</sup>)\n\nAcitretin\n\n(Soriatane<sup>\u00ae</sup>)\n|CNS malformations, outer ear, heart\n\nSkeletal malformations\n|Prescription of exclusive oral contraception, provision of a follow-up booklet\n\nIf pregnant, CPDPN to discuss IMG\n\nPregnancy contraindicated within 2 years of stopping treatment\n<br />Pregnancy\n|-\n|Thymoregulator\n|Lithium (T\u00e9ralithe<sup>\u00ae</sup>)\n|Cardiac malformations (ductus arteriosus, IVC) 4-8 %.\n|In case of pregnancy on lithium, follow-up in CPDPN and foetal echocardiography.\n|-\n|Oral anticoagulants, antivitamins K\n|Warfarin (Coumadine<sup>\u00ae</sup>)\n|Warfarin fetal syndrome 4-6 %.\n\nFacial dysmorphia with short or absent OPN, hypoplasia of the last phalanges of the extremities, premature bone calcifications\n\nCerebral anomalies 2% (microcephaly, hydrocephaly, optic atrophy)\n|Fetal brain ultrasound and MRI to look for abnormalities\n\nPrevention: replacement with LMWH for pregnancy\n\nNo reason to refer patients for abortion\n|-\n|Anti-epileptic drugs\n|Sodium valproate (Depakine<sup>\u00ae</sup>), carbamazepine (Tegretol<sup>\u00ae</sup>)\n|Risks from ''in utero'' exposure during pregnancy:\n\n- spina bifida (6.5 ''vs'' 0.3 \u2030; OR [''Odds Ratio''<nowiki>]: 18.8, CI 95% : [8.4-42.3])</nowiki>\n\n- VIC (11.2 ''vs''<nowiki> 2.7 \u2030; OR: 4.0 [2.2-7.5])</nowiki>\n\n- CIA (19.1 ''vs''<nowiki> 1.9 \u2030; OR: 9.1 [5.6-14.8])</nowiki>\n\n- Pulmonary artery atresia (2.2 ''vs''<nowiki> 0.1 \u2030; OR: 26.2 [3.1-96.6])</nowiki>.\n\n- hypoplasia of the left ventricle (2.2 ''vs''<nowiki>0.1 \u2030; OR: 17.9 [2.1-65.5])</nowiki>.\n\n- Cleft palate (3.4 ''vs''<nowiki>0.7 \u2030; OR: 5.2 [1.1-15.2])</nowiki>\n\n- anorectal atresia (3.4 ''vs''<nowiki> 0.3\u2030; OR: 11.0 [2.3-32.4])</nowiki>\n\n- hypospadias (22.7 ''vs''<nowiki>4.8 \u2030; OR: 4.7 [2.3-9.7])</nowiki>\n\n- Pre-axial polydactyly (2.2 ''vs''<nowiki> 0.2 \u2030; OR: 10.8 [1.3- 39.5])</nowiki>.\n\nOthers on Depakin<sup>\u00ae</sup>: thrombocytopenia, reduced platelet activity, fibrinogen and coagulation factors.\n|Depakine<sup>\u00ae</sup>: essential preconception consultation coupled with a neurological opinion.\n\nRefer to CPDPN in case of exposure and usual prevention with folic acid 5 mg/d\n\nUltrasound for abnormalities including echocardiography\n\nBlood determination of AFP, increased, during serum screening for trisomy 21 (if done in the 2nd<sup>trimester</sup>), suggestive of a neural tube closure anomaly\n|-\n|Prostaglandin 1 analogue (PGE1)\n|Misoprostol (Gymiso<sup>\u00ae</sup>, Misoone<sup>\u00ae</sup>)\n|Moebius syndrome: central paralysis of the 6th</sup>and 7th</sup> cranial pairs, retrognathia, trismus, distal limb abnormalities.\n\nCause: poor foetal vascularisation following induction of uterine contractions in the 1st<sup>trimester</sup> (FC)\n\nMFIU in the 3rd<sup>trimester\n<br />\n|Ultrasound for abnormalities\n\nIndication for monitoring in CPDPN\n|-\n|Immunosuppressant\n|Mycophenolate (Cellcept<sup>\u00ae</sup>, Myfortic<sup>\u00ae</sup>)\n|50% risk of SCF\n\nRisk of malformation of the external ear, cleft lip and palate or nostril, micrognathia, etc.\n|A patient on mycophenolate should have a preconception consultation to change treatment before conception.\n\nIf the patient becomes pregnant, she should consult a doctor to adapt the treatment quickly.\n|-\n|Cancer drugs\n|Methotrexate (Ledertrexate<sup>\u00ae</sup>, Imeth<sup>\u00ae</sup>)\n|Folic acid antagonists: craniostenosis, facial dysmorphia, IUGR, congenital heart disease, FC, etc.\n|Warning of the significant risk of termination of pregnancy\n|-\n|Synthetic antithyroid drugs\n|Carbimazole, (Neo-Mercazole<sup>\u00ae</sup>)\n\nPTU (propylthio-uracil: Propylex<sup>\u00ae</sup>)\n|Scalp aplasia, choanal atresia, oesotracheal fistula and, more rarely, facial dysmorphia and even abdominal wall damage such as omphalocele and gastroschisis.\n\nGoitres observed in foetuses of treated mothers but not always related to PTU but also to basedow's disease (Track)\n|Replace carbimazole in the 1st<sup>term</sup> with PTU, and regularly monitor maternal thyroid function (T4l, T3l, TSHus).\n\nIt can then be taken back because of the maternal liver damage described for PTU\n\nMonitor the foetal thyroid under treatment, especially if TRAK is positive\n\nRisk of maternal hepatotoxicity, so carbimazole should be discussed from the 2nd<sup>trimester</sup>.\n|-\n|Virostatics\n|Ribavirin (Copegus<sup>\u00ae</sup>, Rebetol<sup>\u00ae</sup>)\n\nEfavirenz (Sustiva<sup>\u00ae</sup>)\n|In animals (dose-dependent teratogenicity): malformations of the face (skull, palate, eyes, jaw), limbs, digestive tract and bones.\n\nRisk of non-closure of the neural tube: 0.07%.\n|Prescription under contraception\n\nIf a pregnancy occurs, organise follow-up at the CPDPN\n\nAvoid in the 1<sup>st</sup> trimester\n|}\n\n\n'''312. [[Prevention of foetal risks SD-312|Prevention of foetal risks]]''''\n\n'''340 [[Voluntary or involuntary intake of a toxic or potentially toxic drug SD-340|Voluntary or involuntary intake of a toxic or potentially toxic drug]]''''\n\n'''348. [Suspicion of an adverse drug reaction or an adverse drug treatment SD-348|Suspicion of an adverse drug reaction or an adverse drug treatment]'''''\n\n'''352. [[Explaining treatment to the patient (adult/child/adolescent) SD-352|Explaining treatment to the patient (adult/child/adolescent)]]'''''",
  "question": {
    "question": {
      "title": "Question",
      "description": "Which medication is known to cause fetal malformations, including craniofacial abnormalities and congenital heart disease, when taken during pregnancy?",
      "type": "string"
    },
    "option_a": {
      "title": "Option A",
      "description": "Vitamin A derivatives",
      "type": "string"
    },
    "option_b": {
      "title": "Option B",
      "description": "Thymoregulators (e.g. Lithium)",
      "type": "string"
    },
    "option_c": {
      "title": "Option C",
      "description": "Prostaglandin 1 analogue (PGE1)",
      "type": "string"
    },
    "option_d": {
      "title": "Option D",
      "description": "Cancer drugs (e.g. Methotrexate)",
      "type": "string"
    },
    "correct_option": {
      "title": "Correct Option",
      "description": "Cancer drugs (e.g. Methotrexate)",
      "type": "string"
    }
  }
}